Bristol-Myers Squibb’s CheckMate-9LA trial shows combining nivolumab, ipilimumab, and chemotherapy improves outcomes in advanced NSCLC patients.
Bristol Myers Squibb (BMS) has shared positive four-year follow-up results from a late-stage study of its Opdivo (nivolumab) combination in certain lung cancer patients.
According to the results, which were presented at the American Society of Clinical Oncology annual meeting, the dual immunotherapy-based combination continued to improve overall survival – the trial’s primary endpoint.
With a minimum follow-up of 47.9 months, 21% of patients treated with the dual immunotherapy-based combination alive at four years compared to 16% of patients treated with chemotherapy alone.
With extended follow-up, the clinically meaningful efficacy benefit of the Opdivo combination was maintained across secondary endpoints and key subgroups of patients, the company said, with benefits more pronounced among patients with tumour PD-L1 expression less than 1% and squamous histology.